Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?

Eur J Heart Fail. 2006 Mar;8(2):215; author reply 218. doi: 10.1016/j.ejheart.2006.01.003. Epub 2006 Jan 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • C-Reactive Protein / analysis
  • C-Reactive Protein / drug effects
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Hemodynamics / drug effects
  • Humans
  • Hydrazones / pharmacology
  • Hydrazones / therapeutic use*
  • Interleukin-6 / blood
  • Natriuretic Peptide, Brain / blood
  • Natriuretic Peptide, Brain / drug effects
  • Pyridazines / pharmacology
  • Pyridazines / therapeutic use*
  • Simendan
  • Time Factors
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Interleukin-6
  • Pyridazines
  • Natriuretic Peptide, Brain
  • Simendan
  • C-Reactive Protein